Evidence map›Paper›PMID 34294193›Full record

ArticleThe American journal of pathology2021

Serum Antibodies to N-Glycolylneuraminic Acid Are Elevated in Duchenne Muscular Dystrophy and Correlate with Increased Disease Pathology in Cmah

Paul T Martin, Kunio Kawanishi, Anna Ashbrook, Bethannie Golden, Annie Samraj, Kelly E Crowe, Deborah A Zygmunt, Jonathan Okerblom, Hai Yu, Agatha Maki and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Paul T MartinCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio; Department of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio; Department of Pediatrics, The Ohio State University, Columbus, Ohio. Electronic address: paul.martin@nationwidechildrens.org.
Kunio KawanishiDepartment of Molecular Medicine, University of California, San Diego, California.
Anna AshbrookCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Bethannie GoldenMolecular and Human Genetics, Nationwide Children's Hospital, Columbus, Ohio.
Annie SamrajDepartment of Molecular Medicine, University of California, San Diego, California.
Kelly E CroweGraduate Program in Molecular Cellular and Developmental Biology, The Ohio State University, Columbus, Ohio.
Deborah A ZygmuntCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Jonathan OkerblomDepartment of Molecular Medicine, University of California, San Diego, California.
Hai YuDepartment of Chemistry, University of California, Davis, California.
Agatha MakiCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Sandra DiazDepartment of Molecular Medicine, University of California, San Diego, California.
Xi ChenDepartment of Chemistry, University of California, Davis, California.
Paul M L JanssenDepartment of Physiology and Cell Biology, The Ohio State University, Columbus, Ohio.
Ajit VarkiDepartment of Molecular Medicine, University of California, San Diego, California.
Nationwide Children's Hospital · USUniversity of California San Diego · USThe Ohio State University · USUniversity of California, Davis · US

Funding

BIOSYNTHESIS AND REGULATION OF SUBSTITUTED SIALIC ACIDSR01GM032373 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARKI, AJIT P · 1985 to 2022
$6.9M
Glycosyltransferase Therapy for MyopathiesR01AR049722 · NIAMS · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI MARTIN, PAUL TAYLOR · 2006 to 2018
$4.2M
A new DMD model with a humanized glycomeR01AR060949 · NIAMS · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI MARTIN, PAUL TAYLOR · 2012 to 2016
$2.7M
NIAMS NIH HHS R01 AR049722NIAMS NIH HHS R01 AR060949NIGMS NIH HHS R01 GM032373
6 · The paper itself

Abstract

Humans cannot synthesize the common mammalian sialic acid N-glycolylneuraminic acid (Neu5Gc) because of an inactivating deletion in the cytidine-5'-monophospho-(CMP)-N-acetylneuraminic acid hydroxylase (CMAH) gene responsible for its synthesis. Human Neu5Gc deficiency can lead to development of anti-Neu5Gc serum antibodies, the levels of which can be affected by Neu5Gc-containing diets and by disease. Metabolic incorporation of dietary Neu5Gc into human tissues in the face of circulating antibodies against Neu5Gc-bearing glycans is thought to exacerbate inflammation-driven diseases like cancer and atherosclerosis. Probing of sera with sialoglycan arrays indicated that patients with Duchenne muscular dystrophy (DMD) had a threefold increase in overall anti-Neu5Gc antibody titer compared with age-matched controls. These antibodies recognized a broad spectrum of Neu5Gc-containing glycans. Human-like inactivation of the Cmah gene in mice is known to modulate severity in a variety of mouse models of human disease, including the X chromosome-linked muscular dystrophy (mdx) model for DMD. Cmah

Indexed as

AnimalsAutoantibodiesAutoantigensChildDisease Models, AnimalHumansMaleMiceMice, Inbred mdxMice, KnockoutMuscular Dystrophy, DuchenneNeuraminic AcidsAutoantibodiesAutoantigensNeuraminic AcidsN-glycolylneuraminic acid

Identifiers

PMID34294193
PMCPMC8351128
OpenAlexW3184302992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.